Peptidomimetic Macrocycles Stabilizing p53 Alpha-Helix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant need for compounds that can bind to and modulate the activity of p53, MDM2, and MDMX proteins, as their dysregulation is a common defect in human cancers, leading to cancer and other hyperproliferative diseases.
Innovation Solution
Stably cross-linked peptides, known as p53 peptidomimetic macrocycles, are developed to stabilize the alpha-helical structure of p53, interfering with its binding to MDM2 and MDMX, thereby stabilizing functional p53 and inhibiting its destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional peptides are used to bind p53, then they can modulate p53 activity, but they lack stability and fail to maintain alpha-helical structure
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the alpha-helical structure of the p53 peptide through cross-linking modifications before the peptide encounters MDM2 or MDMX. The cross-linked macrocycle structure is designed in advance to maintain the bioactive conformation, ensuring the peptide remains in the correct structural state for effective binding without requiring post-synthesis folding or stabilization.
Solution Approach 2:
The patent employs composite materials by combining natural amino acid residues with non-natural cross-linking moieties to create a hybrid peptidomimetic macrocycle. This composite structure integrates the biological recognition capabilities of natural peptides with the structural stability of synthetic cross-linked frameworks, achieving both binding activity and enhanced stability.
2Reliability
If p53 binds to MDM2 or MDMX, then p53 transactivation activity is neutralized and p53 is targeted for degradation, but this leads to loss of p53 function in cancer cells
Solution Approach 1:
The patent uses an intermediary approach by introducing a stabilized p53 peptidomimetic macrocycle that acts as a protective mediator between p53 and MDM2/MDMX. This macrocycle binds to p53 and stabilizes its structure, preventing the harmful interaction with MDM2 or MDMX that would lead to p53 degradation and loss of tumor suppressor function.
3Stability of the object's composition
If peptides are modified to improve stability, then they may lose their ability to bind target proteins, but unmodified peptides degrade quickly
Solution Approach 1:
The patent applies local quality by introducing cross-linking modifications only at specific strategic positions within the p53 peptide sequence, rather than uniformly modifying the entire peptide. The cross-links are placed to stabilize the alpha-helical structure while preserving the critical binding interface residues that interact with MDM2 or MDMX, thus maintaining binding capability while enhancing stability.
Data Source
AI summary
Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.